Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC
Clinical trial NCT06607809 · COMPLETED
Trial details
- NCT number
- NCT06607809
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-02-01
- Primary completion
- 2023-01-01
- Enrollment
- 99
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.